The FDA has officially green-lighted the Remicade biosimilar Inflectra, a med from South Korea's Celltrion and Pfizer's ($PFE) Hospira. But will the knockoff be able to capture the same kind of market share from Johnson & Johnson ($JNJ) that it's been stealing in Europe from Merck & Co. ($MRK)? Depends who you ask. More from FiercePharma